HLVX Stock Cash Flow Statements

Hillevax Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Hillevax Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31

cash flows from operating activities
net income	-5,266,000	-6,061,000	-33,947,000	-25,823,000	-40,668,000	-46,829,000	-36,960,000	-31,815,000	-27,902,000	-26,889,000	-21,188,000	-16,805,000	-53,929,000	-67,887,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	241,000	250,000	476,000	476,000	468,000	456,000	429,000	344,000	105,000	1,000
stock-based compensation	2,330,000	2,429,000	4,479,000	5,050,000	6,061,000	5,194,000	3,756,000	3,946,000	3,246,000	2,642,000	1,331,000	844,000	556,000	272,000
amortization of operating lease right-of-use assets	237,000	240,000	378,000	366,000	327,000	251,000	295,000	309,000	313,000	360,000
impairment of long-lived assets			8,364,000	0
amortization of debt discount			0	0	162,000	159,000	157,000	155,000	129,000	126,000	110,000	101,000
issuance (payment) of pik interest debt			0
acquired in-process research and development			0	0	0	15,325,000							0	2,500,000
net accretion/amortization of premiums and discounts on marketable securities	-955,000	-804,000	-460,000	-1,135,000	-1,498,000	-1,299,000
loss on disposal of property and equipment	92,000	148,000									0	0	0	42,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	3,348,000	1,338,000	945,000	-374,000	869,000	-1,160,000	1,590,000	204,000	328,000	1,895,000	-3,120,000	-3,201,000	-4,411,000	-339,000
accounts payable, accrued expenses and other long-term liabilities	-319,000	-9,784,000	2,037,000	-6,679,000	-3,466,000	-5,180,000	9,945,000	-672,000	747,000	4,384,000	3,532,000	-1,263,000
accrued interest			0	-131,000	-4,000	1,000	6,000	26,000	23,000	24,000	29,000	2,000	757,000	2,064,000
operating lease liabilities	-497,000	-474,000								1,409,000
net cash from operating activities	-789,000	-12,718,000	-18,188,000	-27,822,000	-29,779,000	-33,002,000	-21,606,000	-26,806,000	-22,417,000	-15,954,000	-18,517,000	-19,547,000	-13,210,000	-10,715,000
capex	0	0	-110,000	-212,000	-47,000	-153,000	-738,000	-2,186,000	-4,839,000	-2,985,000	0	0	0	0
free cash flows	-789,000	-12,718,000	-18,298,000	-28,034,000	-29,826,000	-33,155,000	-22,344,000	-28,992,000	-27,256,000	-18,939,000	-18,517,000	-19,547,000	-13,210,000	-10,715,000
cash flows from investing activities
cash paid for purchased in-process research and development			0	-1,500,000	0	-13,825,000					0	0	0	-2,500,000
purchases of property and equipment			-110,000	-212,000	-47,000	-153,000	-738,000	-2,186,000	-4,839,000	-2,985,000
purchases of marketable securities	-6,019,000	-111,264,000	1,000	-15,694,000	-46,921,000	-92,684,000	-14,693,000	-43,988,000
proceeds from sales or maturities of marketable securities	18,000,000	17,000,000	69,000,000	68,045,000	43,500,000	49,000,000	44,900,000
net cash from investing activities	11,981,000	-94,264,000	68,891,000	50,639,000	-3,468,000	-57,662,000	29,469,000	-31,174,000	-89,948,000	-2,985,000	-3,829,000	-185,000	0	-2,500,000
cash flows from financing activities
proceeds from issuance of common stock under share-based compensation arrangements			0	0	615,000	175,000
proceeds from issuance of at-the-market offering			0	0	0	14,887,000
net cash from financing activities			0	-27,497,000	615,000	15,062,000	313,000	108,107,000	10,198,000	80,000	9,687,000	-2,820,000	218,201,000	-99,000
net decrease in cash, cash equivalents and restricted cash	11,192,000	-106,982,000	50,703,000	-4,680,000	-32,632,000	-75,602,000				-18,859,000
cash, cash equivalents and restricted cash—beginning of period	0	156,098,000	0	0	0	218,309,000	0	0	0	281,032,000	0	0
cash, cash equivalents and restricted cash—end of period	11,192,000	49,116,000	50,703,000	-4,680,000	-32,632,000	142,707,000	8,176,000	50,127,000	-102,167,000	262,173,000	-12,659,000	-22,552,000
supplemental disclosure of cash flow information
cash paid for interest			0	156,000	387,000	382,000	271,000	660,000	269,000	192,000	89,000	74,000
supplemental disclosure of noncash investing and financing activities
unpaid in-process research and development					0	1,500,000
unpaid property and equipment purchases					311,000	13,000	-35,000	-1,241,000	-2,041,000	3,453,000	1,158,000
accreted final interest payment fees					128,000	124,000	124,000	122,000	108,000	109,000	94,000	88,000
loss on extinguishment of debt			0
operating lease right-of-use assets and liabilities			-460,000	-439,000	-443,000	-94,000	48,000	1,800,000				748,000	750,000	4,000
repayment of long-term debt, including fees			0
proceeds from issuance of common stock in underwritten public offering, net of issuance costs							-310,000
proceeds from issuance of long-term debt, net of issuance costs							0	0			10,000,000	0
unpaid underwritten public offering costs
issuance of pik interest debt					178,000	174,000	173,000	170,000	111,000	94,000	39,000	27,000
change in fair value of convertible promissory notes											0	0	34,396,000	17,073,000
change in fair value of warrant liabilities - related party											0	0	6,151,000	37,424,000
acquired in-process research and development - related party											0
proceeds from issuance of common stock in initial public offering											0	0
payment of initial public offering costs											-313,000	-2,820,000	-16,470,000	-99,000
net increase in cash, cash equivalents and restricted cash							8,176,000	50,127,000			-12,659,000	-22,552,000
operating lease											0	0
conversion of convertible promissory notes and interest into common stock											0
conversion of warrant liability into equity											0	0
settlement of espp liability in common stock
net amortization of premiums and discounts on marketable securities								-1,273,000
proceeds from issuances of stock under espp								0
proceeds from exercise of stock options								7,000	80,000	80,000
unpaid initial public offering costs												-1,411,000	1,176,000	548,000
non-cash lease costs
proceeds from issuance of common stock
proceeds from issuance of convertible promissory notes
accrued interest exchanged for convertible promissory notes
issuance of takeda warrants in connection with takeda license
issuance of common stock in connection with takeda license
purchase of property and equipment
conversion of convertible promissory notes and accrued interest into common stock
accounts payable and accrued expenses														-1,868,000
net decrease in cash and cash equivalents														-13,314,000
cash and cash equivalents—beginning of period														124,566,000
cash and cash equivalents—end of period														111,252,000

We provide you with 20 years of cash flow statements for Hillevax stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Hillevax stock. Explore the full financial landscape of Hillevax stock with our expertly curated income statements.

The information provided in this report about Hillevax stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.